Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease

Liver International

Volumn 33, Issue 7, 2013, Pages 1062-1070

  Youssef, Nagy A ^a   Abdelmalek, Manal F ^b   Binks, Martin ^c   Guy, Cynthia D ^a   Omenetti, Alessia ^b   Smith, Alastair D ^b   Diehl, Anna Mae E ^b   Suzuki, Ayako ^b,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c Binks Behavioral Health PLLC   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Hepatic fibrosis; Hepatocyte ballooning; Liver injury; Mood disorder; Nonalcoholic steatohepatitis

Indexed keywords

ANTIDEPRESSANT AGENT; TRAZODONE;

ADULT; ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; HYPERTENSION; LIVER CELL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; SMOKING; WEIGHT REDUCTION;

HEPATIC FIBROSIS; HEPATOCYTE BALLOONING; LIVER INJURY; MOOD DISORDER; NONALCOHOLIC STEATOHEPATITIS;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; CROSS-SECTIONAL STUDIES; DEPRESSION; FATTY LIVER; FEMALE; HUMANS; LIKELIHOOD FUNCTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; QUESTIONNAIRES;

EID: 84880176434     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12165     Document Type: Article

References (42)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
2. Chitturi S, Farrell GC, George J. Nonalcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004; 19: 368-74.
3. McCullough A. The epidemiology and risk factors of NASH. In: Farrell G, George J, Hall P, McCullough A, eds. Fatty Liver Disease: NASH and Related Disorders. Malden, MA: Blackwell, 2005; 23-37.
4. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994; 20: 1442-9.
5. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
7. Youssef W, McCullough AJ. Diabetes mellitus, obesity, and hepatic steatosis. Semin Gastrointest Dis 2002; 13: 17-30.
8. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002; 35: 1485-93.
9. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7.
10. Weinstein AA, Kallman Price J, Stepanova M, et al. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics 2011; 52: 127-32.
11. Elwing JE, Lustman PJ, Wang HL, Clouse RE. Depression, anxiety and nonalcoholic steatohepatitis. Psychosom Med 2006; 68: 563-9.
12. Lustman PJ, Anderson RJ, Freedland KE, De Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-42.
13. Anderson RJ, Grigsby AB, Freedland KE, et al. Anxiety and poor glycaemic control: a meta-analytic review of the literature. Int J Psychiatry Med 2002; 32: 235-47.
14. Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988; 145: 325-30.
15. Koslow SH, Stokes PE, Mendels J, Ramsey A, Casper R. Insulin tolerance test: human growth hormone response and insulin resistance in primary unipolar depressed, bipolar depressed and control subjects. Psychol Med 1982; 12: 45-55.
16. Lustman PJ, Clouse RE, Ciechanowski PS, Hirsch IB, Freedland KE. Depression-related hyperglycemia in type 1 diabetes: a mediational approach. Psychosom Med 2005; 67: 195-9.
17. Lustman PJ, Griffith LS, Clouse RE, et al. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997; 59: 241-50.
18. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 129: 613-21.
19. Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000; 49: 1255-60.
20. Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology and treatment. Biol Psychiatry 2003; 54: 317-29.
21. Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry 2003; 54: 566-72.
22. Miller GE, Freedland KE, Carney RM, Stetler CA, Banks WA. Pathways linking depression, adiposity and inflammatory markers in healthy young adults. Brain Behav Immun 2003; 17: 276-85.
23. Maes M, Song C, Lin A, et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-18.
24. Fukudo S, Suzuki J, Tanaka Y, Iwahashi S, Nomura T. Impact of stress on alcoholic liver injury; a histopathological study. J Psychosom Res 1989; 33: 515-21.
25. Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol 2010; 298: G335-44.
26. Nocito A, Dahm F, Jochum W, et al. Serotonin mediates oxidative stress and mitochondrial toxicity in a murine model of nonalcoholic steatohepatitis. Gastroenterology 2007; 133: 608-18.
27. Osawa Y, Kanamori H, Seki E, et al. L-tryptophan-mediated enhancement of susceptibility to nonalcoholic fatty liver disease is dependent on the mammalian target of rapamycin. J Biol Chem 2011; 286: 34800-8.
28. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
29. Michopoulos I, Douzenis A, Kalkavoura C, et al. Hospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sample. Ann Gen Psychiatry 2008; 7: 4.
30. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
31. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 2003; 1: 29.
32. Zigmond A, Snaith R. The HADS: Hospital Anxiety and Depression Scale. Windsor NFER Nelson, 1994.
33. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 2006; 63: 1209-16.
34. Johnson S, Stockmeier CA, Meyer JH, et al. The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology 2011; 36: 2139-48.
35. Pena-Silva RA, Miller JD, Chu Y, Heistad DD. Serotonin produces monoamine oxidase-dependent oxidative stress in human heart valves. Am J Physiol Heart Circ Physiol 2009; 297: H1354-60.
36. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with nonalcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
37. Hannestad J, DellaGioia N, Ortiz N, Pittman B, Bhagwagar Z. Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun 2011; 25: 256-9.
38. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab 2005; 1: 53-61.
39. Manjarrez G, Herrera R, Leon M, Hernandez RJ. A low brain serotonergic neurotransmission in children with type 1 diabetes detected through the intensity dependence of auditory-evoked potentials. Diabetes Care 2006; 29: 73-7.
40. Papazoglou I, Berthou F, Vicaire N, et al. Hypothalamic serotonin-insulin signaling cross-talk and alterations in a type 2 diabetic model. Mol Cell Endocrinol 2012; 350: 136-44.
41. Guevara M, Baccaro ME, Gomez-Anson B, et al. Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. J Hepatol 2011; 55: 564-73.
42. Omenetti A, Yang L, Gainetdinov RR, et al. Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. Am J Physiol Gastrointest Liver Physiol 2011; 300: G303-15.